Most researchers seeking out CJC-1295 in Irig immediately realize that local retail options are essentially nonexistent. This matters because CJC-1295 quality differs enormously across the market — from analytically confirmed high-purity product to products with serious contamination — and the vendor determines everything about the product. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide gives Irig researchers the framework to assess vendor quality rigorously and source research-grade CJC-1295 with confidence.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Irig researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors starts with the COA: request the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. For Irig researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Irig
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Temperature excursions — even temporary temperature deviation — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
